Biocodex Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Biocodex Sa (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $21.4M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$21.4M
2024 Medicare Part D Spend$1.7M
2024 Medicaid Spend$19.6M
California HCAI SB 17 Filings20 WAC filings (max 40.5% 2-yr change)